The smart ring is no longer a novelty item. Oura, the Finnish company behind the Oura Ring, has filed for a US initial public offering — and the numbers in its S-1 are the kind that make investors pay attention. According to Economic Times, the company posted annual revenue surpassing $500 million, a figure that signals wearable health tech has moved well beyond fitness-tracker territory into something closer to a mainstream medical data platform. For a company that sells a titanium ring at roughly $300 to $500 a pop, that is a remarkable top line.
Oura’s IPO filing arrives at a moment when the broader health wearables space is heating up fast. Apple, Google, and Samsung are all pushing biometric monitoring deeper into their device ecosystems — but Oura occupies a distinct niche: a ring form factor that tracks sleep, heart rate variability, body temperature, and activity with a level of precision that has earned it clinical credibility with researchers and healthcare providers. That positioning is central to the company’s pitch to public market investors. If you are tracking where the next wave of health monitoring AI is headed, Oura’s trajectory is a strong signal.
What the S-1 Actually Reveals
The filing lays out a business built on two revenue streams: hardware sales and a subscription model. The Oura Ring requires a monthly membership fee — currently $5.99 per month — to unlock the full suite of health insights on the companion app. That recurring revenue layer is critical to how Oura is framing its story for Wall Street. Subscription businesses command higher valuation multiples than pure hardware plays, and Oura is clearly positioning itself closer to the software end of that spectrum even though the ring is the product that gets people in the door.
The company’s last known private valuation stood at approximately $5.2 billion, reached during a 2023 funding round that drew in investors including Temasek. Revenue growth between filing years was steep enough to suggest the company is not simply coasting on early-adopter enthusiasm — it is scaling. The filing also makes clear that Oura’s user base has grown significantly, though the company did not break out exact subscriber counts in early disclosures. Gross margins, a key metric for any hardware-plus-subscription hybrid, were reported as improving year over year, which will be the figure analysts scrutinize most closely as the roadshow begins.
The Competitive Stakes of Going Public Now
Timing matters in an IPO, and Oura’s window is not without risk. The public markets have been lukewarm toward consumer hardware companies in recent years, and the wearables category specifically has seen its share of stumbles. Fitbit’s exit via Google acquisition rather than an independent public run is the cautionary tale that still echoes. But Oura’s profile is different in one meaningful way: its clinical partnerships and research credibility give it a defensible moat that a typical fitness tracker cannot easily replicate. The ring has been used in studies related to COVID-19 detection, fertility tracking, and cardiovascular monitoring — use cases that push it toward the medical device conversation rather than the consumer gadget one.
The IPO also puts competitive pressure on players across the venture landscape. With Oura going public, every smart wearable startup will face harder questions from investors about their own path to profitability and scale. This is the kind of listing that reshapes category expectations — similar to how high-profile raises have recently reset benchmarks in cloud security funding and AI infrastructure. Oura is betting that a ring on your finger can be as data-rich and medically relevant as anything strapped to your wrist — and its S-1 suggests the market is beginning to agree.
